DGIdb - USTEKINUMAB Drug Record

USTEKINUMAB chembl:CHEMBL1201835 ApprovedImmunotherapy

Alternate Names:

STELERA
STELARA
USTEKINUMAB
CNTO-1275
USTEKINUMAB
TT-20
drugbank:05679
chemidplus:815610-63-0
chembl:CHEMBL1201835
rxcui:847083

Drug Info:

FDA Approval	2009
Drug Class	monoclonal antibody
Drug Indications	Antipsoriatic Agents
Year of Approval	2009
Drug Class	antipsoriatic agents

(3 More Sources)

Publications:

van den Reek JMPA et al., 2017, Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis., Br J Dermatol
Talamonti M et al., 2013, Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab., Br J Dermatol
Khanna et al., 2016, The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews., Inflamm. Bowel Dis.
Engel et al., 2016, Ustekinumab in Crohn's disease: evidence to date and place in therapy., Ther Adv Chronic Dis
Wittig, 2007, Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases., Curr Opin Investig Drugs
Reddy et al., 2007, Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275., Cell. Immunol.
Loft ND et al., 2018, Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis., Pharmacogenomics J
Prieto-Pérez R et al., 2017, Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis., Pharmacogenomics

USTEKINUMAB TIRAP

Interaction Score: 12.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28696418

Sources:
PharmGKB
USTEKINUMAB IL12B

Interaction Score: 12.76

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-12 inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
27306074 27433311 27564082 17979029 17761156

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB FDA
USTEKINUMAB TNFAIP3

Interaction Score: 9.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27564082 23521149

Sources:
PharmGKB
USTEKINUMAB AGBL4

Interaction Score: 6.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27977334

Sources:
PharmGKB
USTEKINUMAB TLR5

Interaction Score: 6.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28696418

Sources:
PharmGKB
USTEKINUMAB IL12A

Interaction Score: 6.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-12 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions PharmGKB TTD FDA
USTEKINUMAB IL23A

Interaction Score: 6.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

Mechanism of Interaction Interleukin-23 inhibitor

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD FDA
USTEKINUMAB HLA-C

Interaction Score: 1.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23521149

Sources:
PharmGKB
USTEKINUMAB PDF

Interaction Score: 0.91

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
USTEKINUMAB IL1B

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28696418

Sources:
PharmGKB

TEND: USTEKINUMAB
- Version: 01-August-2011
Alternate Names:

USTEKINUMAB Primary Drug Name

Drug Info:

Drug Class antipsoriatic agents

Year of Approval 2009

Publications:
TdgClinicalTrial: USTEKINUMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antipsoriatic Agents

Drug Class monoclonal antibody

FDA Approval 2009

Publications:

PharmGKB: ustekinumab

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

van den Reek JMPA et al., 2017, Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis., Br J Dermatol

Talamonti M et al., 2013, Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab., Br J Dermatol

Loft ND et al., 2018, Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis., Pharmacogenomics J

TTD: Ustekinumab
- Version: 2020.06.01
Alternate Names:

D0A2UV TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201835
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201835
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Ustekinumab
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Interleukin-12 inhibitor
Direct Interaction	yes
Trial Name	-

Novel drug target	Established target
Trial Name	-
Mechanism of Interaction	Interleukin-23 inhibitor

antibody (inhibitory)
inhibitor (inhibitory)

USTEKINUMAB Drug Record

USTEKINUMAB chembl:CHEMBL1201835 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28696418

Sources: PharmGKB

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Interleukin-12 inhibitor Direct Interaction yes Trial Name -

PMIDs: 27306074 27433311 27564082 17979029 17761156

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27564082 23521149

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27977334

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28696418

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Interleukin-12 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions PharmGKB TTD FDA

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name - Mechanism of Interaction Interleukin-23 inhibitor

PMIDs: None found

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23521149

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28696418

Sources: PharmGKB

TEND: USTEKINUMAB

Alternate Names: USTEKINUMAB Primary Drug Name

Drug Info: Drug Class antipsoriatic agents Year of Approval 2009

Publications:

TdgClinicalTrial: USTEKINUMAB

Alternate Names:

Drug Info: Drug Indications Antipsoriatic Agents Drug Class monoclonal antibody FDA Approval 2009

Publications:

PharmGKB: ustekinumab

Alternate Names:

Drug Info:

TTD: Ustekinumab

Alternate Names: D0A2UV TTD Drug ID

Drug Info:

Publications:

ChemblInteractions: CHEMBL1201835

Alternate Names:

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201835

Alternate Names:

Drug Info:

Publications:

FDA: Ustekinumab

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
28696418

Sources:
PharmGKB

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-12 inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
27306074 27433311 27564082 17979029 17761156

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
27564082 23521149

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27977334

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28696418

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-12 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions PharmGKB TTD FDA

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

Mechanism of Interaction Interleukin-23 inhibitor

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD FDA

Interaction Types & Directionality:

n/a

PMIDs:
23521149

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
28696418

Sources:
PharmGKB

Alternate Names:

USTEKINUMAB Primary Drug Name

Drug Info:

Drug Class antipsoriatic agents

Year of Approval 2009

Drug Info:

Drug Indications Antipsoriatic Agents

Drug Class monoclonal antibody

FDA Approval 2009

Alternate Names:

D0A2UV TTD Drug ID